Show simple item record

dc.contributor.authorLatifoltojar, A
dc.contributor.authorBoyd, K
dc.contributor.authorRiddell, A
dc.contributor.authorKaiser, M
dc.contributor.authorMessiou, C
dc.date.accessioned2020-11-04T12:27:22Z
dc.date.issued2021-01-01
dc.identifier.citationMagnetic resonance imaging, 2021, 75 pp. 60 - 64
dc.identifier.issn0730-725X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4216
dc.identifier.eissn1873-5894
dc.identifier.doi10.1016/j.mri.2020.10.005
dc.description.abstractDiagnosis of patients suspected of multiple myeloma requires a combination of serological and biochemical tests, bone marrow aspirate (BMA) and/or bone marrow trephine (BMT) biopsies as well as complementary information provided by whole-body cross-sectional imaging studies. However, given the heterogeneous nature of multiple myeloma, discrepancies can arise between disease burden on trephine and extent of disease within the marrow on whole-body magnetic resonance imaging (WB-MRI). Here, for the first time, we report on a series of symptomatic multiple myeloma patients for whom there was substantial discordance between disease burden on trephine and WB-MRI.
dc.formatPrint-Electronic
dc.format.extent60 - 64
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCharacterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management.
dc.typeJournal Article
dcterms.dateAccepted2020-10-14
rioxxterms.versionofrecord10.1016/j.mri.2020.10.005
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfMagnetic resonance imaging
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.publication-statusPublished
pubs.volume75
pubs.embargo.termsNot known
icr.researchteamMyeloma Group
dc.contributor.icrauthorKaiser, Martin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0